Literature DB >> 23079322

Endophthalmitis prophylaxis with intracameral cefuroxime in South Africa.

Junet van der Merwe, Hamzah Mustak, Colin Cook.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23079322     DOI: 10.1016/j.jcrs.2012.09.004

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


× No keyword cloud information.
  7 in total

1.  Impact of intracameral cefuroxime on the incidence of postoperative endophthalmitis following cataract surgery in Ireland.

Authors:  N Rahman; C C Murphy
Journal:  Ir J Med Sci       Date:  2014-05-21       Impact factor: 1.568

2.  Intracameral Antibiotics in the Shadow of Hemorrhagic Occlusive Retinal Vasculitis.

Authors:  Ayman Naseri; Ronald B Melles; Neal H Shorstein
Journal:  Ophthalmology       Date:  2017-05       Impact factor: 12.079

Review 3.  Intracameral cefuroxime: prophylaxis of postoperative endophthalmitis after cataract surgery.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

Review 4.  The Routine Use of Intracameral Antibiotics to Prevent Endophthalmitis After Cataract Surgery: How Good is the Evidence?

Authors:  Nicholas K George; Michael W Stewart
Journal:  Ophthalmol Ther       Date:  2018-07-05

5.  Endophthalmitis following Intravitreal Injection, Cataract Surgery, and Vitrectomy: Clinical Features and Visual Outcomes.

Authors:  Ana Maria Cunha; Maria Manuel Iglésias; Amândio Rocha-Sousa; Fernando Falcão-Reis; Manuel Falcão
Journal:  J Ophthalmol       Date:  2021-09-20       Impact factor: 1.909

6.  Cohort study of intracameral moxifloxacin in postoperative endophthalmitis prophylaxis.

Authors:  Virgilio Galvis; Alejandro Tello; Mary Alejandra Sánchez; Paul Anthony Camacho
Journal:  Ophthalmol Eye Dis       Date:  2014-01-16

7.  Intraoperative Cefuroxime Irrigation Prophylaxis for Acute-Onset Endophthalmitis After Phacoemulsification Surgery.

Authors:  Xiubin Ma; Lixin Xie; Yusen Huang
Journal:  Infect Drug Resist       Date:  2020-05-18       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.